A retrospective, observational study to evaluate the effectiveness of Carnitine complex (GODEX®) in patients with nonalcoholic fatty liver disease.

Celltrion Pharm0 个研究点目标入组 30 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•1. 19 ~70 years old (Adult over 19 under the age of 70)
•2. Subjects who were diagnosed with NAFLD
•3. If treated group, subjects who were treated with carnitine complex (824mg PO, TID) for at least 24 weeks form index date
•4. If control group, subjects who were not taking hepatotonic medications at least 24 weeks from index dates

•1. Chronic alcoholic disease
•2. Acute hepatitis A, Viral liver disease, drug induced liver disease, biliary obstruction (Chronic hepatitis B patients without taking antiviral agent are eligible)
•3. Subjects who administered oral hypoglycemic agent including insulin.
•4. Subjects who administered hyperlipidemia medication, antiobestic medication
•5. Subjects who administered hepatotonics except for carnitine complex (Godex cap.)
•6. Subjects with progressive diseases such as malignant tumor
•7. Subjects accompanying active hemorrhage
•8. Other subjects who are not eligible for this study

发起方

Celltrion Pharm